My Treatment Approach: Optimizing Treatment for Chronic GVHD - Episode 12
Medical experts discuss the role of patient-reported outcomes in cGVHD.
Video content above is prompted by the following:
Which PRO measures are most useful for evaluating disease improvement in cGVHD?
Also summarize data with ruxolitinib (Zeiser R, et al. N Engl J Med. 2021) and FDA analysis of ibrutinib PRO data (King-Kallimanis BL, et al. Qual Lif Res. 2020).